Skip to main content

FDA Approvals

Yescarta First CAR T-Cell Therapy FDA Approved for Large B-Cell Lymphoma

Tibsovo Received a New Indication, in Combination with Azacitidine, for Newly Diagnosed Patients with AML and IDH1 Mutation

Vidaza Received New Indication for Patients with Newly Diagnosed Juvenile Myelomonocytic Leukemia

Kymriah Received Accelerated FDA Approval for Relapsed or Refractory Follicular Lymphoma

Opdivo plus Platinum-Based Chemotherapy FDA Approved as First Neoadjuvant Treatment in Early-Stage NSCLC

Lynparza Receives FDA Approval for Adjuvant Treatment of High-Risk Early Breast Cancer with BRCA Mutation

Keytruda Monotherapy FDA Approved for Endometrial Carcinoma with a Biomarker

Carvykti Second BCMA-Directed CAR T-Cell Therapy FDA Approved for Multiple Myeloma

Opdualag, a Novel Immunotherapy Combination, FDA Approved for Advanced Melanoma

Pluvicto FDA Approved for PSMA-Positive Metastatic Prostate Cancer

Page 6 of 21
Results 51 - 60 of 202